---
title: Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel
  in Patients With Acute Coronary Syndrome
date: '2023-08-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37581388/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230815180933&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Background Management of patients with non-ST-segment-elevation acute
  coronary syndrome (NSTE-ACS) is based on 2020 European Society of Cardiology guidelines,
  which recommend the preferential use of prasugrel over ticagrelor. Because the selection
  of the respective P(2)Y(12) inhibitor has to consider label restrictions, we sought
  to evaluate the proportion of patients qualifying for either ticagrelor or prasugrel
  and reasons for noneligibility in an unselected cohort of patients with ...
disable_comments: true
---
Background Management of patients with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the respective P(2)Y(12) inhibitor has to consider label restrictions, we sought to evaluate the proportion of patients qualifying for either ticagrelor or prasugrel and reasons for noneligibility in an unselected cohort of patients with ...